Market Overview

UPDATE: Bank of America Merrill Lynch Initiates Coverage on AbbVie with Buy Rating, $40 PT

Share:
Related ABBV
Abbvie Announces Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA
AbbVie Announces NEJM Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia
August 2016 Update: Dugan Stock Scoring System Mid-January 2016 Purchases Continue Massively Outperforming The S&P 500 (Seeking Alpha)

In a report published Friday, Bank of America Merrill Lynch initiated coverage on AbbVie (NYSE: ABBV) with a Buy rating and $40.00 price target.

BofA Merrill Lynch noted, “ABBV is unique among the US Major Pharma companies given its significant product concentration (45% of 2011 revenues were generated by a single product), Humira. Despite this, we are bullish on ABBV given its attractive valuation, above-average dividend yield, and the potential for the pipeline to deliver a blockbuster HCV franchise over the medium term. We conservatively include no real contribution from the rest of the pipeline despite the fact that we continue to model robust R&D spend.””

AbbVie closed on Thursday at $34.83.

Latest Ratings for ABBV

DateFirmActionFromTo
Jun 2016BMO CapitalDowngradesOutperformMarket Perform
Jun 2016Morgan StanleyDowngradesOverweightEqual-weight
Jun 2016Cowen & CompanyDowngradesOutperformMarket Perform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Initiation Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!